Shoulder Innovations, Inc. (SI) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

Jul 10, 2026

56/ 100

GoAI Score

Hold

Valuation

70

Undervalued

Sentiment

47

Mixed

Risk

44

Elevated Risk

Momentum

68

Gaining

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

Company profile

Company website

Shoulder Innovations, Inc. manufactures medical devices. It has developed a shoulder replacement system. The company was founded by Stephen B. Gunther and Michael DeVries in 2009 and is headquartered in Grand Rapids, MI.

Industry: Medical - Specialties
Sector: Healthcare
Headquarters: US
CEO: Robert Joseph Ball
Listed since: Jul 31, 2025
Employees: 74

Market position

Day range

Current $17.89

$17.785$18.33

52-week range

Current $17.89

$10.92$24.595

Open: $17.95
Previous close: $17.95
Volume: 84.44K; 0.74× average
Average volume: 113.78K; Average daily volume
Market cap: 371.01M USD
Beta: -1.77; Market reference 1
50-day average: $21.1056; -15.24% below average
200-day average: $16.4085; +9.03% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 283.13M USD
P/E (TTM): -10.46×
P/B (TTM): 2.98×
P/S (TTM): 6.18×
EV / EBITDA: -7.64×
Earnings yield: -13.68%
Free cash flow yield: -12.21%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 77.34%
Operating margin: -58.53%
Net margin: -58.33%
Return on equity: -28.67%
Return on assets: -23.75%
Return on invested capital: -16.88%

Financial health

Debt / equity: 0.12×
Current ratio: 11.07×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

47.32M USD+49.63%

Operating income

−26.3M USD-79.46%

Net income

−40.36M USD-158.40%

Financial statements: Income statement
Metric (USD)	FY2025	FY2024	FY2023
Revenue	47.32M USD	31.62M USD	19.27M USD
Cost of goods sold	11.12M USD	7.28M USD	4M USD
Gross profit	36.2M USD	24.34M USD	15.27M USD
Research and development	7.73M USD	4.49M USD	3.02M USD
Selling, general, and administrative	54.77M USD	34.51M USD	23.11M USD
Operating expenses	62.5M USD	38.99M USD	26.13M USD
Interest expense	70K USD	1.32M USD	761K USD
Depreciation and amortization	3.21M USD	2.2M USD	1.64M USD
Operating income	−26.3M USD	−14.65M USD	−10.86M USD
Net income	−40.36M USD	−15.62M USD	−12.66M USD

Company facts updated Sep 17, 2026.

Earnings

EPS beat rate: 40%; 2 beats, 3 misses, 0 met estimates
Average EPS surprise: -2029.08%; 5 comparable reports
Latest EPS result: -0.46; Estimate -0.46 · Miss by 0.32%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

4 ratings

Limited analyst sample: 4 ratings. Interpret the distribution with caution.

Strong buy00%

Buy4100%

Hold00%

Sell00%

Strong sell00%

Recent analyst actions

4 institutions

UBSmaintainBuyAug 10, 2026

Morgan StanleymaintainOverweightDec 2, 2025

SI news

seekingalpha.comSep 16, 2026

Shoulder Innovations, Inc. (SI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Read source

prnewswire.comSep 10, 2026

Shoulder Innovations Receives FDA 510(k) Clearance for N-22 Humeral Head and Initiates Full Commercial Launch

Second Product Introduction on New Line of Technologies for Metal-Sensitive Patients GRAND RAPIDS, Mich., Sept. 10, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations", or "the company") (NYSE: SI), a…

Read source

prnewswire.comSep 9, 2026

Shoulder Innovations Announces Exclusive Partnership with ALM Ortho to Introduce Bespoke Solution for Complex Shoulder Reconstruction Procedures

GRAND RAPIDS, Mich., Sept. 9, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations", or "the company") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the…

Read source

prnewswire.comSep 8, 2026

Shoulder Innovations Announces Settlement of Patent Litigation with Catalyst OrthoScience

GRAND RAPIDS, Mich., Sept. 8, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical…

Read source

prnewswire.comSep 1, 2026

Shoulder Innovations to Participate in the Morgan Stanley 24th Annual Healthcare Conference

GRAND RAPIDS, Mich., Sept. 1, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the…

Read source

prnewswire.comAug 10, 2026

Shoulder Innovations Promotes Jon Osborne to Chief Commercial Officer

GRAND RAPIDS, Mich., Aug. 10, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the…

Read source

SI peers

LLY

Eli Lilly and Company

$1,138.21

+0.18%

JNJ

Johnson & Johnson

$267.28

+0.03%

ABBV

AbbVie Inc.

$262.58

-0.17%

MRK

Merck & Co., Inc.

$144.95

+0.81%

UNH

UnitedHealth Group Incorporated

$375.26

-0.18%

NVS

Novartis AG

$138.7

+0.06%

Shoulder Innovations, Inc.

SI company overview

Company profile

Shoulder Innovations, Inc.

SI company overview

GoAI snapshot

Company profile

Market position

Financials

Financial snapshot

Valuation & yield

Profitability & efficiency

Financial health

Financial statements

Margin trends

Income trends

Earnings

EPS: actual versus estimate

Revenue: actual versus estimate

Analyst ratings

Rating distribution

Recent analyst actions

SI news

Shoulder Innovations, Inc. (SI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Shoulder Innovations Receives FDA 510(k) Clearance for N-22 Humeral Head and Initiates Full Commercial Launch

Shoulder Innovations Announces Exclusive Partnership with ALM Ortho to Introduce Bespoke Solution for Complex Shoulder Reconstruction Procedures

Shoulder Innovations Announces Settlement of Patent Litigation with Catalyst OrthoScience

Shoulder Innovations to Participate in the Morgan Stanley 24th Annual Healthcare Conference

Shoulder Innovations Promotes Jon Osborne to Chief Commercial Officer

SI peers

Continue in GoAI

SI company overview

Company profile

Market position

SI company overview

Company profile

SI company overview

Company profile

Market position

SI company overview

GoAI snapshot

Company profile

Market position

Financials

Financial snapshot

Valuation & yield

Profitability & efficiency

Financial health

Financial statements

Margin trends

Income trends

Earnings

EPS: actual versus estimate

Revenue: actual versus estimate

Analyst ratings

Rating distribution

Recent analyst actions

SI news

Shoulder Innovations, Inc. (SI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Shoulder Innovations Receives FDA 510(k) Clearance for N-22 Humeral Head and Initiates Full Commercial Launch

Shoulder Innovations Announces Exclusive Partnership with ALM Ortho to Introduce Bespoke Solution for Complex Shoulder Reconstruction Procedures

Shoulder Innovations Announces Settlement of Patent Litigation with Catalyst OrthoScience

Shoulder Innovations to Participate in the Morgan Stanley 24th Annual Healthcare Conference

Shoulder Innovations Promotes Jon Osborne to Chief Commercial Officer

SI peers

Continue in GoAI